Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines reports developments for a central nervous system precision neuroscience biopharmaceutical company focused on therapies for disorders involving neuronal excitation-inhibition imbalance. Its recurring updates cover the Cerebrum small molecule platform, the Solidus antisense oligonucleotide platform, and product candidates across movement disorders and epilepsy, including ulixacaltamide, relutrigine, vormatrigine and elsunersen.
Company news commonly addresses FDA review activity, clinical trial data, scientific presentations, operating and financial results, commercial-readiness updates, equity inducement grants under Nasdaq rules and governance matters. Disease areas highlighted in its disclosures include essential tremor and developmental and epileptic encephalopathies associated with SCN2A and SCN8A.
Praxis Precision Medicines (NASDAQ: PRAX) said the FDA accepted its New Drug Application for relutrigine and granted priority review, assigning a PDUFA target action date of September 27, 2026.
The NDA is supported by the EMBOLD study, which stopped early for efficacy, and relutrigine holds Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations. If approved, relutrigine would be the first FDA-approved therapy for SCN2A and SCN8A developmental and epileptic encephalopathies and eligible for a Pediatric Review Voucher. The EMERALD trial is expected to complete by the end of 2026.
Praxis Precision Medicines (Nasdaq: PRAX) announced on March 4, 2026 that its Compensation Committee granted restricted stock unit awards covering 2,931 shares to fourteen new non-executive employees under the 2024 Inducement Plan.
The awards were granted on March 2, 2026 as inducements under Nasdaq Listing Rule 5635(c)(4) and vest in four equal annual installments, subject to continued employment on each vesting date.
Praxis Precision Medicines (NASDAQ: PRAX) reported Q4 and full-year 2025 results and provided a corporate update. Key developments include two NDA submissions for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs), Breakthrough Therapy designations, and multiple 2026 topline readouts.
Financials: $926.1M cash at 12/31/2025, $621.2M net proceeds in Jan 2026, and funding expected into 2028; 2025 net loss $303.3M and R&D $267.1M.
Praxis Precision Medicines (NASDAQ: PRAX) will report fourth quarter and full year 2025 financial results and provide a corporate update before markets open on February 19, 2026 at 8:00 am ET. The company will host a conference call and live webcast; replays will be available on the Events & Presentations page for ~90 days.
Management will present at Guggenheim Biotech Summit on Feb 11, 2026 and TD Cowen Health Care Conference on Mar 2, 2026, with live webcasts and subsequent replays.
Praxis Precision Medicines (Nasdaq: PRAX) announced that on February 2, 2026 the Compensation Committee granted restricted stock unit awards covering an aggregate of 2,964 shares to eight new non-executive employees under the 2024 Inducement Plan.
The awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4) and will vest in four equal annual installments, subject to continued employment on each vesting date.
Praxis Precision Medicines (NASDAQ: PRAX) on Jan 13, 2026 appointed Dr. Orrin Devinsky as Head of Clinical Strategy, a new leadership role reporting to Steven Petrou, Ph.D., President of Research and Development.
Dr. Devinsky brings more than 40 years of clinical experience, > 500 peer-reviewed publications, 16 issued patents, leadership on pivotal cannabidiol trials for rare epilepsies, and prior direction of a major academic epilepsy program. He will guide clinical program architecture, evidence generation, and global medical affairs as Praxis advances a late-stage portfolio toward commercialization.
Praxis Precision Medicines (NASDAQ: PRAX) outlined 2026 priorities after a pivotal 2025 that produced multiple late‑stage successes. The company expects two NDA submissions by mid‑February 2026 for ulixacaltamide (essential tremor) and relutrigine (SCN2A/8A DEEs), both with FDA Breakthrough Therapy Designation. Multiple pivotal readouts across vormatrigine, relutrigine and elsunersen are planned in 2026. Praxis reports a strong pro forma balance sheet of approximately $1.5 billion and completed a January 2026 public offering with net proceeds of ~$621 million. The company cites combined peak revenue potential for four late‑stage assets exceeding $20 billion.
Praxis Precision Medicines (Nasdaq: PRAX) announced that on January 2, 2026 its Compensation Committee granted restricted stock unit awards covering an aggregate of 434 shares to three new non-executive employees under the 2024 Inducement Plan.
The awards were granted as inducements material to the employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously employees or who return after a bona fide period of non-employment. The restricted stock units vest in four equal annual installments, subject to continued employment on each vesting date.
Praxis Precision Medicines (NASDAQ: PRAX) announced board additions and senior executive promotions on January 8, 2026 to support a transition into late-stage development and commercial readiness. Jeffrey B. Kindler and Stuart Arbuckle joined the board to strengthen experience in global launches, strategic transactions, and commercial scaling. Megan Sniecinski was promoted to Chief Operating Officer to lead operational execution and corporate development, and Dr. Steven Petrou was promoted to President of Research & Development to oversee the full R&D continuum. The release highlights Praxis's late-stage pipeline and a successful ulixacaltamide Phase 3 program as the company prepares for potential registration and commercialization.
Praxis Precision Medicines (NASDAQ: PRAX) priced an underwritten public offering of 2,212,000 common shares at $260.00 per share, with gross proceeds of about $575 million before underwriting discounts and expenses. The company granted underwriters a 30‑day option to purchase up to 331,800 additional shares (15% overallotment). The offering is expected to close on or about January 8, 2026, subject to customary closing conditions and market conditions. The offering is being made from a shelf registration that became effective December 23, 2024; a preliminary prospectus supplement was filed January 6, 2026.